Literature DB >> 8958311

Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas.

M Z Gilcrease1, L Truong, R W Brown.   

Abstract

Cell adhesion molecules mediate cell-cell and cell-matrix interactions, and they are thought to play an important role in tumor invasion and metastasis. Altered expression of integrins and CD44 in renal cell carcinoma has been recently demonstrated, but an association with invasive or metastatic behavior has not been reported. We examined very late activation (VLA) integrin and CD44 expression in 37 renal cell carcinomas and correlated adhesion molecule expression with multiple histological and clinical parameters. Most tumors exhibited positive staining for VLA3 (81%). Approximately one third of the tumors stained positively for VLA6 and CD44, and fewer (27%) were positive for VLA2. Only a few tumors were positive for VLA4 (8%) and VLA5 (14%). Most of the tumors exhibiting positive staining showed a combination of membranous and cytoplasmic staining patterns. Low-grade tumors positive for VLA6 showed a tendency for basilar staining of the tumor cells, whereas high-grade tumors exhibited diffuse cytoplasmic staining. All tumors exhibiting weak or strong positive staining for VLA4 or VLA5 showed extrarenal invasion or were known to have developed metastases at the time of nephrectomy. All tumors strongly positive for VLA2 or CD44 showed invasion beyond the renal capsule or metastases. In contrast to a previous study, no association was observed between positive staining and tumor grade. Nor were tumor size, architectural pattern, cell type, or DNA ploidy found to be associated with particular staining patterns. Although many of the invasive tumors showed no difference in VLA integrin or CD44 expression compared with tumors confined to the kidney, increased expression in some of them suggests that these cell adhesion molecules may contribute to the invasive or metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958311     DOI: 10.1016/s0046-8177(96)90350-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.

Authors:  Mukaddes Gumustekin; Aydanur Kargi; Gulay Bulut; Aysim Gozukizil; Cagnur Ulukus; Ilhan Oztop; Nese Atabey
Journal:  Pathol Oncol Res       Date:  2011-07-21       Impact factor: 3.201

2.  Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies.

Authors:  Yan Ren; Piliang Hao; Bamaprasad Dutta; Esther Sok Hwee Cheow; Kae Hwan Sim; Chee Sian Gan; Sai Kiang Lim; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2012-11-30       Impact factor: 5.911

3.  Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Cem Terzi; Aras Emre Canda; Ozgul Sagol; Koray Atila; Devrim Sonmez; Mehmet Fuzun; Ilknur B Gorken; Ilhan Oztop; Funda Obuz
Journal:  Int J Colorectal Dis       Date:  2007-09-06       Impact factor: 2.571

4.  Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases.

Authors:  So Dug Lim; Andrew N Young; Gladell P Paner; Mahul B Amin
Journal:  Virchows Arch       Date:  2007-11-20       Impact factor: 4.064

5.  Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.

Authors:  Evren Yilmaz; Meral Koyuncuoglu; Ilknur Bilkay Görken; Emre Okyay; Bahadir Saatli; Emine Cagnur Ulukus; Ugur Saygili
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

6.  Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.

Authors:  F Laube; B Göhring; H Sann; I Willhardt
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.